| Effect | Decrease |
| Trial Design | Double blind |
| Trial Length | 1-6 months |
| Number of Subjects | 127 |
| Gender | Both Genders |
| Age Range | 30-44, 45-64 |
| Body Types | Overweight |
_L. reuteri_ NCIMB 30242 in hypercholesterolemic adults over nine weeks at the dose of 2.9x10^9^ twice daily appeared to be able to reduce circulating LDL cholesterol (11.64%) and total cholesterol (9.14%) with an additional reduction of apolipoprotein B100 (8.41%) with no effect on HDL-C or triglycerides.Funding issues for this study:
All benefits reported took six weeks, as there were no changes when reported at three weeks.
CRP and fibrinogen were also noted to be reduced with supplementation.
Conducted by researchers involved with Micropharma, producers of this particular strain
| Effect | None |
| Trial Design | Double blind |
| Trial Length | 1-6 months |
| Number of Subjects | 114 |
| Gender | Both Genders |
| Age Range | 30-44, 45-64 |
| Body Types | Overweight |
_L. reuteri_ NCIMB at 5x10^9^ CFU daily for six weeks in persons with high cholesterol was able to moderately reduce both LDL cholesterol (8.92%) and total cholesterol (4.81%) with no influence on fecal bile acids nor other parameters of cardiovascular health.Funding issues for this study:
Safety testing found supplementation to be well tolerated.
Some authors reported a potential conflict of interest as they are involved with the company which produces this strain (Micropharma limited)